418 reports of this reaction
3.2% of all ELETRIPTAN HYDROBROMIDE reports
#5 most reported adverse reaction
PAIN is the #5 most commonly reported adverse reaction for ELETRIPTAN HYDROBROMIDE, manufactured by ROERIG. There are 418 FDA adverse event reports linking ELETRIPTAN HYDROBROMIDE to PAIN. This represents approximately 3.2% of all 13,057 adverse event reports for this drug.
Patients taking ELETRIPTAN HYDROBROMIDE who experience pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PAIN is moderately reported among ELETRIPTAN HYDROBROMIDE users, representing a notable but not dominant share of adverse events.
In addition to pain, the following adverse reactions have been reported for ELETRIPTAN HYDROBROMIDE:
The following drugs have also been linked to pain in FDA adverse event reports:
PAIN has been reported as an adverse event in 418 FDA reports for ELETRIPTAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PAIN accounts for approximately 3.2% of all adverse event reports for ELETRIPTAN HYDROBROMIDE, making it a notable side effect.
If you experience pain while taking ELETRIPTAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.